Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

New technique predicts post-stroke recovery

A team of researchers led by NewYork-Presbyterian Hospital/Columbia University Medical Center has developed a method to predict post-stroke recovery of language by measuring the initial severity of impairment.

25 Jun 2010

Phadia's four new EliA autoimmune antibody assays receive FDA clearance

Today Phadia announced that it has received FDA 510 (K) clearance for four new EliA autoimmune antibody assays. These new assays will provide physicians with additional tools needed to aid in the diagnosis of Antiphospholipid Syndrome. The newly available EliA assays, anti-cardiolipin (aCL) IgG/IgM and anti-B2-glycoprotein 1 (anti-B2-GP1) IgG/IgM, have proven to be essential, sensitive, and specific markers to aid in the diagnosis of APS.

25 Jun 2010

Mercy Hospital signs letter of intent to sell its facility to HCA

Today, Hospital Corporation of America, together with Mercy Hospital, announced they had entered into a letter of intent for the sale of the hospital to HCA. Mercy's board of directors voted to sell the facility to HCA, citing the company's presence in South Florida and consistent provision of quality care.

25 Jun 2010

AGA refused permission to appeal UK Supreme Court for Figulla ASD and PFO occluder patent infringement

In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.

24 Jun 2010

Group of tests may help predict falls in people with Parkinson's disease: Study

A group of tests may help predict which people with Parkinson's disease are more likely to fall, according to a study published in the June 23, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

24 Jun 2010

Ways to manage hammertoe pain

The pain from hammertoe, a deformity that can cause one or more toes to assume a claw shape, can curtail an evening of dancing or make a favorite pair of shoes unwearable. But, according to the June issue of Mayo Clinic Health Letter, this condition often can be managed by proper footwear or simple toe coverings.

24 Jun 2010

NIH to invest $25M over five years for international collaboration on genetic research in Africa

The NIH on Tuesday announced a partnership with Wellcome Trust and the African Society for Human Genetics that will enable African researchers to "use the latest genetic and clinical technology to study common health problems, such as cardiovascular disease, cancer and other diseases," VOA News reports (DeCapua, 6/22).

24 Jun 2010

Spherix to explore triglycerides for D-tagatose therapy

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.

24 Jun 2010

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Researchers at UT Southwestern Medical Center have pinpointed a set of biological mechanisms through which estrogen confers its beneficial effects on the cardiovascular system, independent of the hormone's actions on cancer. Their investigation suggests that drugs targeting a specific subpopulation of estrogen receptors found outside the cell nucleus might activate the cardiovascular benefits of estrogen without increasing cancer risk.

24 Jun 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

Biosense Webster's CARTOXPRESS Module, LASSO NAV Circular Mapping Catheter receive FDA clearance

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today that the U.S. Food and Drug Administration (FDA) has cleared for marketing the CARTOXPRESS™ Software Module and the LASSO® NAV Circular Mapping Catheter for use with the CARTO® XP Mapping System.

24 Jun 2010

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.

24 Jun 2010

Hidden heart condition raise stroke and heart failure risk: Report

According to the National Stroke Foundation a hidden and largely undetected heart condition is costing the Australian economy over $1.2 billion a year. In a report released today the Foundation has said that Atrial Fibrillation (AF), commonly manifested as severe irregularity of heart beat and palpitation that may go unnoticed is affecting more than 240,000 Australians at present with half over the age of 75.

23 Jun 2010

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).

23 Jun 2010

BioDigital, NYU Langone partner to create Right Upper Lobe Resection Cognitive Task Trainer

SensAble Technologies, a leader in haptic devices and 3D modeling solutions, announced that its customer, BioDigital, working in partnership with surgeons at NYU Langone Medical Center, has created the first medical simulation application for teaching residents the high-technology procedure for lung resection of the right upper lobe, most commonly performed to treat resectable lung cancers.

23 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease.

23 Jun 2010

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Patients who had experienced a heart attack and lowered their blood homocysteine levels with folic acid and vitamin B12 supplementation did not have an associated lower risk of heart attack, coronary death or stroke, according to a study in the June 23/30 issue of JAMA. However, the researchers did find that folic acid supplementation did not increase the risk of cancer, which has been speculated.

23 Jun 2010

Stroke News and Research

Further Reading

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

New technique predicts post-stroke recovery

Phadia's four new EliA autoimmune antibody assays receive FDA clearance

Mercy Hospital signs letter of intent to sell its facility to HCA

AGA refused permission to appeal UK Supreme Court for Figulla ASD and PFO occluder patent infringement

Group of tests may help predict falls in people with Parkinson's disease: Study

Ways to manage hammertoe pain

NIH to invest $25M over five years for international collaboration on genetic research in Africa

Spherix to explore triglycerides for D-tagatose therapy

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Biosense Webster's CARTOXPRESS Module, LASSO NAV Circular Mapping Catheter receive FDA clearance

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

Hidden heart condition raise stroke and heart failure risk: Report

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

BioDigital, NYU Langone partner to create Right Upper Lobe Resection Cognitive Task Trainer

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News